
    
      This is a 12-week, randomized, double-blind, double dummy, placebo-controlled study designed
      to assess the effects of the cholesterol absorption inhibitor HS-25 (10mg or 20mg) or in
      combination with Atorvastatin (10mg) on LDL-C levels in adults who have untreated LDL-C
      levels ranging from 3.36-4.88mmol/L(130-189 mg/dL)and fasting triglyceride levels < 350
      mg/dL. Eligibility is restricted to 18-70 years old men or women who are using a highly
      effective birth control method or are not of childbearing potential;subjects with not treated
      by statins in six months before signature of the informed consent.Subjects with diabetes, a
      history of myocardial infarction or other clinical evidence of atherosclerotic vascular
      disease or treated are not eligible for participation in the study.
    
  